<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168178</url>
  </required_header>
  <id_info>
    <org_study_id>91955</org_study_id>
    <nct_id>NCT03168178</nct_id>
  </id_info>
  <brief_title>Intrapartum Fever: Antibiotics Versus no Treatment</brief_title>
  <official_title>A Randomized Trial in Intrapartum Fever Of No Antibiotics for Low-risk Women (RATIONAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether antibiotics can be safely avoided in women
      who develop a fever during labor. Because investigators have no accurate tests to determine
      whether women who develop fever during labor have intra-amniotic infection, antibiotics are
      often used to prevent spread of infection to the fetus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A fever &gt; 100.4 F during labor (intrapartum fever) complicates up to 14% of term deliveries,
      and is commonly considered a sign of intrauterine infection. Despite studies showing that
      most causes of maternal intrapartum fever are non-infectious, intrapartum fever often prompts
      the diagnosis of chorioamnionitis/intrauterine infection, or what is now known as 'triple I'
      (intra-amniotic infection or inflammation). Diagnosis of triple I is primarily based on
      clinical findings such as maternal fever, maternal leukocytosis, uterine tenderness,
      foul-smelling or purulent amniotic fluid, and fetal tachycardia. A minimum of two of these
      criteria for diagnosis, although this distinction is somewhat artificial as fetal tachycardia
      is highly associated with maternal fever. The poor performance of clinical signs and lack of
      effective biomarkers to identify neonatal infection results in over treatment of both mothers
      and infants.

      Avoiding antibiotic use in mothers and infants is desirable in order to avoid unnecessary
      separation after birth, decreasing cost and interventions in newborns, and to avoid altering
      the infant's microbiome (the bacteria newborns carry on their skin, mucosal membranes, and in
      their gut at the time of birth). Infants with altered microbiomes may be at risk for skin,
      pulmonary, and gastrointestinal disorders. The investigators in this trial are randomizing
      women with fever during labor who are felt to be a low risk for true infection to antibiotic
      treatment compared to no antibiotics in order to determine if antibiotics can be safely
      avoided for these women and their infants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Low risk women will be randomized to standard antibiotic treatment versus no antiobiotics.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal antibiotic treatment as recommended by the EONS (Early Onset Neonatal Sepsis) calculator.</measure>
    <time_frame>Within 2 hours of delivery</time_frame>
    <description>All newborns will have a screening assessment including physical exam and vital signs, and this data along with maternal and delivery data is entered into the Kaiser Permanente Early Onset Neonatal Sepsis (EONS) calculator. The EONS calculator estimates the risk of sepsis and recommends observation, additional evaluation, or empiric antibiotic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive blood culture</measure>
    <time_frame>Up to 4 days after birth</time_frame>
    <description>For infants who have a blood culture obtained by recommendation of the EONS calculator, the presence of significant bacterial growth will be considered a positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for NICU admission</measure>
    <time_frame>Up to 4 weeks after birth</time_frame>
    <description>Admission of the infant to the Newborn Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newborn length of stay</measure>
    <time_frame>Up to 4 weeks after birth</time_frame>
    <description>Days hospitalized after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal endometritis</measure>
    <time_frame>Up to 4 weeks after birth</time_frame>
    <description>The diagnosis of endometritis made by the patient's OB provider requiring treatment with antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal length of stay</measure>
    <time_frame>Up to 4 weeks after birth</time_frame>
    <description>Days hospitalized after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
    <description>Satisfaction with maternal and newborn care using a standardized survey administered by phone at 6-8 weeks after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost</measure>
    <time_frame>Up to 4 weeks after birth</time_frame>
    <description>The hospital charges for mother and infant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Chorioamnionitis</condition>
  <condition>Intrapartum Fever</condition>
  <condition>Intra-amniotic Infection</condition>
  <arm_group>
    <arm_group_label>Standard Antibiotic Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Antibiotic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Antibiotic Treatment</intervention_name>
    <description>Participants randomized to this intervention will receive standard antibiotic treatment.
The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes</description>
    <arm_group_label>Standard Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Antibiotic Treatment</intervention_name>
    <description>Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes</description>
    <arm_group_label>No Antibiotic Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women between 34-42 weeks gestation

          -  Singleton fetus

          -  Admitted for labor management &amp; develops a fever of 100.4 F or greater

        Exclusion Criteria:

          -  Known fetal anomaly

          -  Other indication for intrapartum antibiotics (endocarditis prophylaxis, other known
             maternal infection)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Campbell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Campbell, MD</last_name>
    <phone>(801) 581-8425</phone>
    <email>heather.campbell@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Gibson</last_name>
    <phone>(801) 213-2845</phone>
    <email>marie.gibson@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah, Department of Obstetrics &amp; Gynecology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Campbell, MD</last_name>
      <phone>801-581-8425</phone>
      <email>heather.campbell@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Gibson</last_name>
      <phone>(801) 213-2845</phone>
      <email>marie.gibson@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smulian JC, Bhandari V, Vintzileos AM, Shen-Schwarz S, Quashie C, Lai-Lin YL, Ananth CV. Intrapartum fever at term: serum and histologic markers of inflammation. Am J Obstet Gynecol. 2003 Jan;188(1):269-74.</citation>
    <PMID>12548228</PMID>
  </reference>
  <reference>
    <citation>Smulian JC, Shen-Schwarz S, Vintzileos AM, Lake MF, Ananth CV. Clinical chorioamnionitis and histologic placental inflammation. Obstet Gynecol. 1999 Dec;94(6):1000-5.</citation>
    <PMID>10576190</PMID>
  </reference>
  <reference>
    <citation>Roberts DJ, Celi AC, Riley LE, Onderdonk AB, Boyd TK, Johnson LC, Lieberman E. Acute histologic chorioamnionitis at term: nearly always noninfectious. PLoS One. 2012;7(3):e31819. doi: 10.1371/journal.pone.0031819. Epub 2012 Mar 7.</citation>
    <PMID>22412842</PMID>
  </reference>
  <reference>
    <citation>Taylor JA, Opel DJ. Choriophobia: a 1-act play. Pediatrics. 2012 Aug;130(2):342-6. doi: 10.1542/peds.2012-0106. Epub 2012 Jul 9.</citation>
    <PMID>22778303</PMID>
  </reference>
  <reference>
    <citation>Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, Newman TB, Zupancic J, Lieberman E, Draper D. Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks' gestation. Pediatrics. 2014 Jan;133(1):30-6. doi: 10.1542/peds.2013-1689. Epub 2013 Dec 23.</citation>
    <PMID>24366992</PMID>
  </reference>
  <reference>
    <citation>Cuna A, Hakima L, Tseng YA, Fornier B, Islam S, Quintos-Alagheband ML, Khullar P, Weinberger B, Hanna N. Clinical dilemma of positive histologic chorioamnionitis in term newborn. Front Pediatr. 2014 Apr 4;2:27. doi: 10.3389/fped.2014.00027. eCollection 2014.</citation>
    <PMID>24772410</PMID>
  </reference>
  <reference>
    <citation>Evers AC, Nijhuis L, Koster MP, Bont LJ, Visser GH. Intrapartum fever at term: diagnostic markers to individualize the risk of fetal infection: a review. Obstet Gynecol Surv. 2012 Mar;67(3):187-200. doi: 10.1097/OGX.0b013e31824bb5f1. Review.</citation>
    <PMID>22901952</PMID>
  </reference>
  <reference>
    <citation>Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG. 2005 Feb;112(2):173-81.</citation>
    <PMID>15663581</PMID>
  </reference>
  <reference>
    <citation>Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Poindexter BB, Van Meurs KP, Bizzarro MJ, Goldberg RN, Frantz ID 3rd, Hale EC, Shankaran S, Kennedy K, Carlo WA, Watterberg KL, Bell EF, Walsh MC, Schibler K, Laptook AR, Shane AL, Schrag SJ, Das A, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011 May;127(5):817-26. doi: 10.1542/peds.2010-2217. Epub 2011 Apr 25. Erratum in: Pediatrics. 2011 Aug;128(2):390.</citation>
    <PMID>21518717</PMID>
  </reference>
  <reference>
    <citation>Newman TB, Puopolo KM, Wi S, Draper D, Escobar GJ. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics. 2010 Nov;126(5):903-9. doi: 10.1542/peds.2010-0935. Epub 2010 Oct 25.</citation>
    <PMID>20974782</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Heather Campbell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Chorioamnionitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

